Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Brean Murray Downgrades Adolor

Brean Murray downgrades Adolor Corp. (ADLR) to sell from hold.

Analyst Jonathan Aschoff says he originally expected the trial to be positive, but not overwhelmingly so, and therefore recommended selling into strength that he believed the trial would provide.

However, given the failed primary endpoint, he does not recommend owning Adolor shares in anticipation of a positive FDA Advisory Panel outcome. He says he cannot understand why this latest trial achieved statistical significance in a secondary endpoint that is less forgiving than its primary endpoint.

Aschoff believes the FDA Advisory Panel will not recommend approval of alvimopan for postoperative ileus.

blog comments powered by Disqus